(PAHC) Phibro Animal Health - Overview
Sector: HealthcareIndustry: Drug Manufacturers - Specialty & Generic | Exchange NASDAQ (USA) | Currency USD | Market Cap: 2.181m | Total Return 168.6% in 12m
Stock: Animal Health, Mineral Nutrition, Specialty Ingredients
Total Rating 80
Risk 80
Buy Signal 1.15
| Risk 5d forecast | |
|---|---|
| Volatility | 48.4% |
| Relative Tail Risk | -17.1% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 2.06 |
| Alpha | 142.01 |
| Character TTM | |
|---|---|
| Beta | 1.360 |
| Beta Downside | 3.388 |
| Drawdowns 3y | |
|---|---|
| Max DD | 38.10% |
| CAGR/Max DD | 1.59 |
EPS (Earnings per Share)
Revenue
Description: PAHC Phibro Animal Health March 05, 2026
Phibro Animal Health Corporation (PAHC) is an animal health and mineral nutrition company with global operations.
The company operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The Animal Health segment develops and markets products for various food and companion animals, including antibacterials, anticoccidials, nutritional specialties, and vaccines. This segment is a key player in the animal health industry, which focuses on improving animal well-being and food safety.
The Mineral Nutrition segment provides trace minerals to fortify livestock diets. The Performance Products segment offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries.
PAHC sells its animal health and mineral nutrition products directly to integrated producers and through commercial feed manufacturers, wholesalers, and distributors. The companys business model involves both direct sales and distribution networks, common in the animal agriculture supply chain.
Further research into PAHCs financials and market position can provide a deeper understanding of its investment profile.
Headlines to watch out for
- Global livestock disease outbreaks increase demand for animal health products
- Regulatory changes impacting antibiotic use in food animals
- Commodity price fluctuations influence animal feed additive costs
- Currency exchange rates affect international sales and profitability
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income: 92.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA 2.17 > 1.0 |
| NWC/Revenue: 39.60% < 20% (prev 46.37%; Δ -6.78% < -1%) |
| CFO/TA 0.07 > 3% & CFO 93.1m > Net Income 92.1m |
| Net Debt (717.7m) to EBITDA (226.0m): 3.18 < 3 |
| Current Ratio: 3.05 > 1.5 & < 3 |
| Outstanding Shares: last quarter (41.0m) vs 12m ago 0.59% < -2% |
| Gross Margin: 31.89% > 18% (prev 0.32%; Δ 3.16k% > 0.5%) |
| Asset Turnover: 108.8% > 50% (prev 86.04%; Δ 22.79% > 0%) |
| Interest Coverage Ratio: 3.64 > 6 (EBITDA TTM 226.0m / Interest Expense TTM 48.1m) |
Altman Z'' 4.51
| A: 0.41 (Total Current Assets 862.2m - Total Current Liabilities 282.4m) / Total Assets 1.41b |
| B: 0.23 (Retained Earnings 317.0m / Total Assets 1.41b) |
| C: 0.13 (EBIT TTM 175.2m / Avg Total Assets 1.35b) |
| D: 0.18 (Book Value of Equity 194.6m / Total Liabilities 1.07b) |
| Altman-Z'' Score: 4.51 = AA |
Beneish M -2.89
| DSRI: 0.85 (Receivables 215.9m/191.8m, Revenue 1.46b/1.11b) |
| GMI: 1.00 (GM 31.89% / 31.83%) |
| AQI: 1.05 (AQ_t 0.13 / AQ_t-1 0.13) |
| SGI: 1.32 (Revenue 1.46b / 1.11b) |
| TATA: -0.00 (NI 92.1m - CFO 93.1m) / TA 1.41b) |
| Beneish M-Score: -2.89 (Cap -4..+1) = A |
What is the price of PAHC shares?
As of March 26, 2026, the stock is trading at USD 57.01 with a total of 480,991 shares traded.
Over the past week, the price has changed by +9.15%, over one month by +7.61%, over three months by +49.70% and over the past year by +168.57%.
Over the past week, the price has changed by +9.15%, over one month by +7.61%, over three months by +49.70% and over the past year by +168.57%.
Is PAHC a buy, sell or hold?
Phibro Animal Health has received a consensus analysts rating of 2.50.
Therefor, it is recommend to sell PAHC.
- StrongBuy: 0
- Buy: 0
- Hold: 2
- Sell: 2
- StrongSell: 0
What are the forecasts/targets for the PAHC price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 48.5 | -14.9% |
| Analysts Target Price | 48.5 | -14.9% |
PAHC Fundamental Data Overview March 25, 2026
P/E Trailing = 23.8053
P/E Forward = 10.5708
P/S = 1.4893
P/B = 6.1931
P/EG = 1.6618
Revenue TTM = 1.46b USD
EBIT TTM = 175.2m USD
EBITDA TTM = 226.0m USD
Long Term Debt = 710.6m USD (from longTermDebt, last quarter)
Short Term Debt = 29.6m USD (from shortTermDebt, last quarter)
Debt = 773.2m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 717.7m USD (from netDebt column, last quarter)
Enterprise Value = 2.88b USD (2.18b + Debt 773.2m - CCE 74.5m)
Interest Coverage Ratio = 3.64 (Ebit TTM 175.2m / Interest Expense TTM 48.1m)
EV/FCF = 60.89x (Enterprise Value 2.88b / FCF TTM 47.3m)
FCF Yield = 1.64% (FCF TTM 47.3m / Enterprise Value 2.88b)
FCF Margin = 3.23% (FCF TTM 47.3m / Revenue TTM 1.46b)
Net Margin = 6.29% (Net Income TTM 92.1m / Revenue TTM 1.46b)
Gross Margin = 31.89% ((Revenue TTM 1.46b - Cost of Revenue TTM 997.3m) / Revenue TTM)
Gross Margin QoQ = 35.48% (prev 32.92%)
Tobins Q-Ratio = 2.05 (Enterprise Value 2.88b / Total Assets 1.41b)
Interest Expense / Debt = 1.69% (Interest Expense 13.1m / Debt 773.2m)
Taxrate = 24.61% (8.97m / 36.4m)
NOPAT = 132.1m (EBIT 175.2m * (1 - 24.61%))
Current Ratio = 3.05 (Total Current Assets 862.2m / Total Current Liabilities 282.4m)
Debt / Equity = 2.33 (Debt 773.2m / totalStockholderEquity, last quarter 332.4m)
Debt / EBITDA = 3.18 (Net Debt 717.7m / EBITDA 226.0m)
Debt / FCF = 15.18 (Net Debt 717.7m / FCF TTM 47.3m)
Total Stockholder Equity = 298.9m (last 4 quarters mean from totalStockholderEquity)
RoA = 6.84% (Net Income 92.1m / Total Assets 1.41b)
RoE = 30.81% (Net Income TTM 92.1m / Total Stockholder Equity 298.9m)
RoCE = 17.36% (EBIT 175.2m / Capital Employed (Equity 298.9m + L.T.Debt 710.6m))
RoIC = 12.84% (NOPAT 132.1m / Invested Capital 1.03b)
WACC = 8.28% (E(2.18b)/V(2.95b) * Re(10.77%) + D(773.2m)/V(2.95b) * Rd(1.69%) * (1-Tc(0.25)))
Discount Rate = 10.77% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.56%
[DCF] Terminal Value 70.28% ; FCFF base≈34.5m ; Y1≈23.5m ; Y5≈11.6m
[DCF] Fair Price = N/A (negative equity: EV 216.8m - Net Debt 717.7m = -500.9m; debt exceeds intrinsic value)
EPS Correlation: 76.71 | EPS CAGR: 29.50% | SUE: 4.0 | # QB: 2
Revenue Correlation: 87.43 | Revenue CAGR: 12.60% | SUE: 1.86 | # QB: 3
EPS current Year (2026-06-30): EPS=3.02 | Chg7d=+0.295 | Chg30d=+0.295 | Revisions Net=+3 | Growth EPS=+44.7% | Growth Revenue=+14.8%
EPS next Year (2027-06-30): EPS=3.36 | Chg7d=+0.345 | Chg30d=+0.345 | Revisions Net=+4 | Growth EPS=+11.2% | Growth Revenue=+3.8%
[Analyst] Revisions Ratio: +1.00 (3 Up / 0 Down within 30d for Current Year)
[Growth] Implied Growth Rate = 6.6% (Discount Rate 10.8% - Earnings Yield 4.2%)
[Growth] Growth Spread = -2.8% (Analyst 3.8% - Implied 6.6%)
P/E Forward = 10.5708
P/S = 1.4893
P/B = 6.1931
P/EG = 1.6618
Revenue TTM = 1.46b USD
EBIT TTM = 175.2m USD
EBITDA TTM = 226.0m USD
Long Term Debt = 710.6m USD (from longTermDebt, last quarter)
Short Term Debt = 29.6m USD (from shortTermDebt, last quarter)
Debt = 773.2m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 717.7m USD (from netDebt column, last quarter)
Enterprise Value = 2.88b USD (2.18b + Debt 773.2m - CCE 74.5m)
Interest Coverage Ratio = 3.64 (Ebit TTM 175.2m / Interest Expense TTM 48.1m)
EV/FCF = 60.89x (Enterprise Value 2.88b / FCF TTM 47.3m)
FCF Yield = 1.64% (FCF TTM 47.3m / Enterprise Value 2.88b)
FCF Margin = 3.23% (FCF TTM 47.3m / Revenue TTM 1.46b)
Net Margin = 6.29% (Net Income TTM 92.1m / Revenue TTM 1.46b)
Gross Margin = 31.89% ((Revenue TTM 1.46b - Cost of Revenue TTM 997.3m) / Revenue TTM)
Gross Margin QoQ = 35.48% (prev 32.92%)
Tobins Q-Ratio = 2.05 (Enterprise Value 2.88b / Total Assets 1.41b)
Interest Expense / Debt = 1.69% (Interest Expense 13.1m / Debt 773.2m)
Taxrate = 24.61% (8.97m / 36.4m)
NOPAT = 132.1m (EBIT 175.2m * (1 - 24.61%))
Current Ratio = 3.05 (Total Current Assets 862.2m / Total Current Liabilities 282.4m)
Debt / Equity = 2.33 (Debt 773.2m / totalStockholderEquity, last quarter 332.4m)
Debt / EBITDA = 3.18 (Net Debt 717.7m / EBITDA 226.0m)
Debt / FCF = 15.18 (Net Debt 717.7m / FCF TTM 47.3m)
Total Stockholder Equity = 298.9m (last 4 quarters mean from totalStockholderEquity)
RoA = 6.84% (Net Income 92.1m / Total Assets 1.41b)
RoE = 30.81% (Net Income TTM 92.1m / Total Stockholder Equity 298.9m)
RoCE = 17.36% (EBIT 175.2m / Capital Employed (Equity 298.9m + L.T.Debt 710.6m))
RoIC = 12.84% (NOPAT 132.1m / Invested Capital 1.03b)
WACC = 8.28% (E(2.18b)/V(2.95b) * Re(10.77%) + D(773.2m)/V(2.95b) * Rd(1.69%) * (1-Tc(0.25)))
Discount Rate = 10.77% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.56%
[DCF] Terminal Value 70.28% ; FCFF base≈34.5m ; Y1≈23.5m ; Y5≈11.6m
[DCF] Fair Price = N/A (negative equity: EV 216.8m - Net Debt 717.7m = -500.9m; debt exceeds intrinsic value)
EPS Correlation: 76.71 | EPS CAGR: 29.50% | SUE: 4.0 | # QB: 2
Revenue Correlation: 87.43 | Revenue CAGR: 12.60% | SUE: 1.86 | # QB: 3
EPS current Year (2026-06-30): EPS=3.02 | Chg7d=+0.295 | Chg30d=+0.295 | Revisions Net=+3 | Growth EPS=+44.7% | Growth Revenue=+14.8%
EPS next Year (2027-06-30): EPS=3.36 | Chg7d=+0.345 | Chg30d=+0.345 | Revisions Net=+4 | Growth EPS=+11.2% | Growth Revenue=+3.8%
[Analyst] Revisions Ratio: +1.00 (3 Up / 0 Down within 30d for Current Year)
[Growth] Implied Growth Rate = 6.6% (Discount Rate 10.8% - Earnings Yield 4.2%)
[Growth] Growth Spread = -2.8% (Analyst 3.8% - Implied 6.6%)